高校加强行政管理改革面临的问题及对策思考

加强高校行政管理改革,是我国高等教育进入大众化阶段的必然要求。本文分析了高校行政管理中泛行政化、官僚化以及在制度创新和人员素质方面存在的一些问题,提出了落实科学发展观,更新高校行政管理理念;汲取院校研究成果,创新高校行政管理制度;运用新公共管理理论,改善泛行政化、官僚化现象等几项对策。     

英法大部门政府体制的实践与启示

本文对英法大部门政府体制的理论起源、部门构成与演变、部门内外协调机制进行了分析,总结了其成功的经验和实施的制度基础,指出完善的市场经济、成熟的社会自治、政府职能的及时更新、配套改革措施到位是英法大部制成功运作的基础。与此相应,在我国推动相应的改革必须着力强化部门首长的协调与控制能力、围绕职能行使效率设计部门结构、推进相应的综合配套改革。     

结构现实主义外交政策理论的构建与拓展——兼论对理解中国外交政策的启示

基于当下外交政策研究领域所呈现出的理论有效供给不足的局面,国际关系理论界围绕外交政策能否建立简约系统的理论以及结构现实主义外交政策理论是否可行展开了争论。本文对既有争论进行了回顾和梳理,剖析了结构现实主义外交政策理论的必要性与可行性。在此基础上,深入评估了进攻性现实主义、防御性现实主义与新古典现实主义等现实主义理论分支在外交政策理论探索中的进展与不足。同时,本文对结构现实主义外交政策理论的拓展进行了尝试,试图开拓出更加纯粹、有力的理论发展路径,完善结构现实主义外交政策理论的解释力。最后,运用结构现实主义外交政策理论剖析了中国外交存在的规律性现象,并剖析了其在未来外交政策构建中可能得到的体现与拓展。     

低标准住宅改造的政府定位与模式选择

对20世纪70-80年代修建的一大批低标准民用住房的改造是当前城市面临的一大任务。本文以北京市为例,结合低标准住房存在的主要问题,分析了对其进行改造的目标和模式选择,并重点论述了政府在这一过程中的作用定位。本文的结论是,在目前的条件下,住房改造需要政府主导,但同时政府应当避免高度行政化的思维取向,更多地选择有管理的市场化的路径。     

《北京市供热采暖管理办法》解读——立法的必要性、基本思路及宣贯要求

正2009年11月10日,北京市人民政府第52次常务会议审议并通过了《北京市供热采暖管理办法》(以下简称《办法》),并作为市政府第216号令予以公布。《办法》将于2010年4月1日起正式施行。这标志着北京新的供热采暖管理制度的确立,也预示着北京供热采暖新的秩序即将建立。     

Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule

This final rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to reschedule buprenorphine from a Schedule V narcotic to a Schedule III narcotic under the Controlled Substances Act (CSA). This action is based on a rescheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that buprenorphine meets the criteria of a Schedule III narcotic. The DEA published a proposed rule to reschedule buprenorphine on March 21, 2002 (67 FR 13114). The comment period was extended for an additional 30 days until May 22, 2002 (67 FR 20072). The DEA received ten comments but no requests for hearings. This final action will impose the regulatory controls and criminal sanctions of a Schedule III narcotic on those persons who handle buprenorphine or products containing buprenorphine     

Food labeling: health claims; soluble dietary fiber from certain foods and coronary heart disease. Interim final rule

The Food and Drug Administration (FDA) is amending the regulation authorizing a health claim on the relationship between beta-glucan soluble fiber from whole oat sources and reduced risk of coronary heart disease (CHD). The amendment adds as an additional eligible source of whole oat beta-glucan soluble fiber, the soluble fraction of alpha-amylase hydrolyzed oat bran or whole oat flour with a beta-glucan soluble fiber content of up to 10 percent on a dry weight basis (dwb) and not less than that of the starting material (dwb). We (FDA) are taking this action in response to a petition jointly filed by the Quaker Oats Co. and Rhodia, Inc. (the petitioners). We concluded previously that there was significant scientific agreement that a relationship exists between the beta-glucan soluble fiber of certain whole oat sources and the reduction of risk of CHD by lowering blood cholesterol levels. We now have concluded, based on the publicly available scientific evidence that, in addition to rolled oats, oat bran, and whole oat flour, the soluble fraction of alpha-amylase hydrolyzed oat bran or whole oat flour with a beta-glucan content up to 10 percent (dwb) and not less than that of the starting material (dwb) is an appropriate source of beta-glucan soluble fiber for the health claim. Therefore, we are amending the regulation that authorizes a health claim on the relationship between soluble fiber from whole oats and reduced risk of CHD to include this additional source of beta-glucan soluble fiber.     

Cold,cough, allergy,bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule

The Food and Drug Administration (FDA) is issuing a final rule in the form of a final monograph that establishes conditions under which over-the-counter (OTC) cold, cough, allergy, bronchodilator, and antiasthmatic (cough-cold) combination drug products are generally recognized as safe and effective and not misbranded as part of its ongoing review of OTC drug products. FDA is issuing this final rule after considering public comments on the agency's proposed regulation (tentative final monograph) and new data and information on OTC cough- cold combination drug products that have come to the agency's attention.     

Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule

The Food and Drug Administration (FDA) is issuing a final rule amending the final monographs for over-the-counter (OTC) antiemetic, antihistamine, antitussive, and nighttime sleep-aid drug products to add a warning statement for oral products containing diphenhydramine citrate or diphenhydramine hydrochloride. The warning advises consumers not to use oral OTC diphenhydramine products with any other product containing diphenhydramine, including products used topically. This final rule also includes the agency's conclusions on additional warning statements and a direction statement for OTC external analgesic drug products containing diphenhydramine hydrochloride. These conclusions will be incorporated into the final monograph for OTC external analgesic drug products in a future issue of the Federal Register. FDA is issuing this final rule after considering public comments on the agency's proposed regulation and all new data and information on drug products containing diphenhydramine that have come to the agency's attention     

Dental devices; classification for intraoral devices for snoring and/or obstructive sleep apnea. Final rule

The Food and Drug Administration (FDA) is classifying the intraoral devices for snoring and/or obstructive sleep apnea into class II (special controls). These devices are used to control or treat simple snoring and/or obstructive sleep apnea. This classification is based on the recommendations of the Dental Devices Panel (the Panel), and is being taken to establish sufficient regulatory controls that will provide reasonable assurance of the safety and effectiveness of these devices. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device Amendments of 1976 (the 1976 amendments), the Safe Medical Devices Act of 1990 (the SMDA), and the Food and Drug Administration Modernization Act of 1997 (FDAMA). Elsewhere in this issue of the Federal Register, FDA is publishing a notice of availability of the guidance document that will serve as the special control for this final rule.